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The epithelial-mesenchymal transition (EMT) contributes to cancer
metastasis. Two ZEB family members, ZEB1 and ZEB2(SIP1), inhibit
transcription of the E-cadherin gene and induce EMT in vitro.
However, their relevance to human cancer is insufficiently studied.
Here, we performed a comparative study of SIP1 and ZEB1 proteins
in cancer cell lines and in one form of human malignancy, carci-
noma of the bladder. Whereas ZEB1 protein was expressed in all
E-cadherin-negative carcinoma cell lines, being in part responsible
for the high motility of bladder cancer cells, SIP1 was hardly ever
detectable in carcinoma cells in culture. However, SIP1 represented
an independent factor of poor prognosis (P  0.005) in a series of
bladder cancer specimens obtained from patients treated with
radiotherapy. In contrast, ZEB1 was rarely expressed in tumor
tissues; and E-cadherin status did not correlate with the patients’
survival. SIP1 protected cells from UV- and cisplatin-induced apo-
ptosis in vitro but had no effect on the level of DNA damage. The
anti-apoptotic effect of SIP1 was independent of either cell cycle
arrest or loss of cell-cell adhesion and was associated with reduced
phosphorylation of ATM/ATR targets in UV-treated cells. The
prognostic value of SIP1 and its role in DNA damage response
establish a link between genetic instability and metastasis and
suggest a potential importance for this protein as a therapeutic
target. In addition, we conclude that the nature of an EMT pathway
rather than the deregulation of E-cadherin per se is critical for the
progression of the disease and patients’ survival.
Epithelial mesenchymal transition (EMT) is a genetic programcontrolling cell migration during embryonic development
and in wound healing (1, 2). Aberrant activation of EMT
programs occurs in cells of epithelial tumors and contributes to
the formation of cancer stem cells and metastasis (1–4). EMT is
characterized by the loss of epithelial and the acquisition of
mesenchymal features. EMT programs are controlled by several
master regulators including TWIST, SNAIL (SNAI1 and
SNAI2), and ZEB (ZEB1/EF1/TCF8 and SIP1/ZEB2) protein
family members. These proteins act downstream in EMT-
inducing signal transduction pathways activated by growth fac-
tors, integrin engagement and hypoxia (1–3). Their expression is
tightly regulated at the posttranscriptional level. Recent reports
highlighted the importance of miR-200 microRNA family in the
regulation of ZEB1 and SIP1 protein expression (5). ZEB
proteins bind proximal E-boxes within the E-cadherin gene
(cdh1) promoter and repress transcription by recruiting core-
pressor complexes (6). Likewise, they directly repress numerous
genes encoding components of the epithelial junctional complex
and cell polarity factors (7, 8). The relevance of ZEB proteins to
tumor progression has been studied in several forms of human
cancer. Expression of ZEB1 correlated with the aggressive
phenotype in various histological types of endometrial carci-
noma and was detected in sarcomatous compartment of endo-
metrial carcinosarcoma (9). In colon cancer, ZEB1 was ex-
pressed at the invasive front of tumors, in association with the
transient loss of basement membranes (10). Reciprocal expres-
sion of ZEB1 and E-cadherin has been observed in non-small
cell lung carcinoma (11). A direct correlation between ZEB1
immunoreactivity and Gleason grade in human prostate tumors
has been reported (12). Up-regulation of SIP1 in several cancer
types has been demonstrated by RT-PCR (13, 14). However,
given that posttranscriptional mechanisms are important factors
in the control of SIP1 abundance, the level of SIP1 mRNA does
not necessarily reflect protein expression; therefore, RT-PCR
data have to be interpreted with caution.
Here, we analyzed expression and EMT-related functions of ZEB1
and SIP1 proteins in human cancer cell lines and in specimens of
transitional cell carcinoma (TCC) of the bladder. TCCs represent the
absolute majority of bladder tumors and are divided into two types,
non-muscle invasive (70%) and muscle invasive (15). In many cases,
muscle invasive TCC manifest metastatic features that represent a
major cause of death. EMT-related events (cadherin switch, loss or
aberrant expression of catenins) have been observed in muscle-invasive
TCCs (16). We found that two ZEB proteins exhibit different patterns
of expression in TCC of the bladder, with SIP1 being a strong candidate
for driving progression in bladder cancer. This observation is consistent
with our data describing an anti-apoptotic function of SIP1 in DNA
damage response. In contrast, ZEB1 is expressed in E-cadherin-
negative carcinoma cell lines and is in part responsible for enhanced
motility of bladder cancer cells.
Results
E-cadherin, ZEB1, and SIP1 Immunostaining and Clinical Outcomes. As
no comparative immunohistochemical examination of ZEB family
members in any type of malignancy has been published to date, we
performed such a study in bladder TCC samples from 134 patients.
To detect SIP1, we raised poly- and monoclonal antibodies against
N-terminal 380 amino acid residue fragment of human SIP1. Both
antibodies specifically detected myc-tagged mouse SIP1 protein in
western blotting and IHC methods (Fig. S1). Patients were derived
from two clinical groups; muscle invasive [n  77 (grade 2, n  12;
Author contributions: A.E.S., M.K., and E.T. designed research; A.E.S., R.P., G.J.B., A.R., R.E.,
H.Q., S.G., S.F., K.S., and K.J.B. performed research; T.Y., N.J.M., K.S., G.D.D.J., and A.C.
contributed new reagents/analytic tools; A.E.S., T.R.G., J.K.M., M.K., and E.T. analyzed data;
and E.T. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1To whom correspondence should be addressed at: Department of Cancer Studies and
Molecular Medicine, University of Leicester, Hodgkin building, Lancaster Road, Leicester
LE1 9HN, United Kingdom. E-mail: et32@le.ac.uk.
This article contains supporting information online at www.pnas.org/cgi/content/full/
0902042106/DCSupplemental.
14884–14889  PNAS  September 1, 2009  vol. 106  no. 35 www.pnas.orgcgidoi10.1073pnas.0902042106
grade 3, n  65)] and grade 3 non-muscle invasive [T1 (n  41), Ta
(n  16)]. Whereas E-cadherin negativity was infrequent (6/134
[4.4%]), aberrant E-cadherin staining was common in this series
[81/134 (60%)] (Fig. S2A). Aberrant or absent expression of
E-cadherin significantly correlated with higher tumor stage ( T2
vs. T1 vs. Ta, P  0.014; 2 test). Of 134 tumor specimens stained
for ZEB1, only 10 (7.5%) expressed ZEB1 protein either diffusely
(5/134) or focally (5/134). In all ZEB1-positive specimens, ZEB1
staining was strong and primarily nuclear (Fig. S2B). The extent of
ZEB1 immunopositivity inversely correlated with E-cadherin stain-
ing (P  0.0001, r  0.369, Spearman correlation). Stromal cells
consistently showed nuclear ZEB1 staining in all specimens. Anal-
ysis of SIP1 expression was performed in 128 specimens with a 1C6
monoclonal antibody (Fig. S2C). To confirm the specificity of the
staining, parallel sections of 20 samples were analyzed with a
commercial polyclonal antibody recognizing an epitope located
between amino acid residues 500 and 600 of SIP1 (Santa-Cruz
Biotech). Two antibodies raised against different epitopes in SIP1
protein demonstrated nearly identical staining patterns (Fig. S3). In
the majority of specimens, staining was predominantly nuclear; in
some samples cytoplasmic localization was also observed. Nuclear
staining was scored as negative (-), weak (-/), strong (), or very
strong (); and we then defined immunonegativity as absent or
weak nuclear staining. Of 128 tumors, 31 (24%) demonstrated
strong or very strong SIP1 staining which inversely correlated with
E-cadherin expression (P  0.030, Fisher’s exact test). Neither SIP1
nor ZEB1 staining was observed in nonmalignant bladder urothe-
lium (Fig. S2D).
Of the 134 patients, treatment modalities used and clinical
follow-up were available for 125. Of these, 85 were treated with
radiotherapy, 27 with Bacillus Calmette-Guerin (bacillus Calmette-
Guérin), 11 with endoscopic follow-up, and 2 with radical cystec-
tomy. Fifty-four were alive or had sustained a non TCC-related
death, whereas 71 had died of bladder TCC. We identified 76
patients with muscle-invasive TCC treated with radical radiother-
apy and with complete follow-up for whom we correlated E-
cadherin (n  76), ZEB1 (n  76), and SIP1 (n  72) immuno-
staining with cancer-specific survivals. The median follow-up was
17 months (Range: 4 to 120 months). Aberrant or absent E-
cadherin staining compared with normal E-cadherin immunoreac-
tivity did not predict TCC-related death (P  0.258, Log rank test)
(Fig. 1A). This is in agreement with the results of a previous
comprehensive study evaluating prognostic significance of E-
cadherin status in bladder cancer (16). Similarly, ZEB1 staining did
not correlate with cancer-specific survival (P  0.217, Log rank test)
(Fig. 1B). However, patients with SIP1-immunopositive tumors
were more likely to die of TCC compared with those who had
SIP1-negative bladder tumors (P  0.005, Log rank test) (Fig. 1C).
Cumulative survival at 5 years for patients with SIP1 immunon-
egative tumors was 42% compared with only 11% for those with
SIP1 immunopositive tumors. Of 14 patients alive at 5 years
follow-up, 12 were SIP1-immunonegative. Although we have shown
SIP1 immunopositivity to be a predictor of cancer-specific survival,
a correlation between SIP1 expression levels, and lack of local
response in the bladder to radiotherapy was statistically not signif-
icant. However, we observed a trend toward better response to this
treatment in patients with SIP1-negative tumors (Fig. 1D).
ZEB Family Members and Mesenchymal Phenotype in Cultured Cells.
We analyzed transcription of ZEB proteins in five bladder cancer
cell lines derived from muscle invasive TCC and in the RT4 cell line
originating from a superficial bladder papilloma. Morphologically,
these cell lines represented two distinct types, epithelial (RT4,
RT112, and HT1376) and mesenchymal (T24, UMUC3, and J82).
Accordingly, cells of the first group expressed epithelial cadherins,
whereas transcription of N-cadherin was detected exclusively in
mesenchymal cell lines (Fig. 2A). Transcription of ZEB1 and SIP1
genes (zfhx1a and zfhx1b) was high in mesenchymal but low or
absent in epithelial cells. Given that SIP1 and ZEB1 abundance is
regulated post-transcriptionally, we analyzed their expression at
protein level. Interestingly, full length SIP1 protein was expressed
only in T24 cells; and its expression level was low. In contrast,
approximately 140 kDa ZEB1-immunoreactive bands were de-
tected in all carcinoma cell lines possessing mesenchymal features
(Fig. 2B). The perfect inverse correlation between ZEB1 and
E-cadherin levels in bladder cancer cell lines prompted us to analyze
Fig. 1. Cancer-specific survival of patients with muscle invasive TCC treated with radical radiotherapy according to immuno-positivity of (A) E-cadherin; (B) ZEB1; (C)
SIP1. Note that SIP1 positivity, but not E-cadherin status or ZEB1 levels predict the outcome of the disease. (D) Proportion of tumors with a lack of response to
radiotherapy divided into groups according to SIP1 or E-cadherin immunopositivity. SIP(-), no SIP1-positive cells detected in the sample; SIP(/), samples mostly
negative, but with a few areas with faintly stained cells; SIP1(), samples with 20–50% cells having strong nuclear staining; SIP1(), 50% cells with strong nuclear
staining. E-cad(), membranous localization of E-cadherin throughout the whole section; E-cad(-, -/), E-cadherin staining is absent either completely or focally.
Examples of staining patterns are available as SI Methods (Fig. S2). Dotted line shows a percentage of nonresponding tumors in the whole series (n  56). The data
demonstrate a trend toward a lack of response to radiotherapy in patients with SIP1-positive tumors.








the effect of ZEB1 on E-cadherin promoter activity. ZEB, SNAI,
Twist, and E47 proteins repress E-cadherin transcription by inter-
acting with two proximal E-boxes within the E-cadherin promoter.
We used transient transfection assays with luciferase reporters
driven either by wild-type or a mutant E-cadherin core promoter
containing mutated E-boxes 1 and 2. Data obtained showed that
ZEB1 was primarily responsible for the silencing E-cadherin pro-
moter in E-cadherin-negative bladder cancer cells (Fig. S4).
Having demonstrated lack of SIP1 expression in E-cadherin-
negative bladder cancer cell lines, we asked whether this is a general
feature of carcinoma cell lines derived from other tumor types.
Except for H1299 lung carcinoma cells, none of the carcinoma cell
lines analyzed expressed SIP1. In contrast, we detected high levels
of SIP1 protein in two out of three sarcoma cell lines. ZEB1
expression perfectly correlated with the lack of E-cadherin in all cell
lines analyzed (Fig. 2C).
To address the functional aspects of ZEB proteins in bladder
cancer cells, we transiently expressed ZEB1 or SIP1 in epithelial
RT112 cells followed by double immunofluorescence staining for
ZEB proteins along with the EMT markers. Cells expressing ZEB1
or SIP1 showed a tendency for localization at the periphery of
clusters formed by groups of nontransfected cells. Expression of
either ZEB1 or SIP1 lead to the disappearance of epithelial
cadherins and cadherin-associated -catenin from cell-cell borders.
In addition, ZEB1 activated expression of N-cadherin (Fig. S5).
In breast cancer cells, ZEB1 inhibition reactivated expression of
E-cadherin and induced other EMT features (8). However, in
contrast to MDA-231 breast carcinoma cells, knockdown of ZEB1
was insufficient to reactivate epithelial markers in J82 or UMUC-3
cells (Fig. S6). Despite this, ZEB1 depletion impaired cell motility
by 50–80% in J82, UMUC-3, or MDA-231 cells independently of
reexpression of epithelial cadherins (Fig. S6). Previously, we de-
scribed Rb-cyclin D1-dependent cell cycle arrest in A431 cells
expressing SIP1 (17). To address whether both ZEB proteins affect
G1/S phase transition, we used ScanR̂ microscopy. By determining
DNA content in cells expressing ZEB proteins and in MOCK-
transfected cells we found that SIP1, but not ZEB1, significantly
attenuated G1/S transition in RT112 cells (Fig. S7).
SIP1 Protects Bladder Cancer Cells from DNA-Damage-Induced Apo-
ptosis. Given a trend toward a worse response to radiotherapy
existed in patients with SIP1-positive bladder tumors (Fig. 1D), we
wished to investigate whether SIP1 interferes with DNA-damage-
induced apoptotic pathways. To this end, we generated a mixed
population of RT112 cells with doxycycline- (DOX)-regulated
expression of myc-tagged SIP1 in 60–70% of the cells (Fig. 3A).
RT112/SIP1 cells were treated with UV, and 16 h later DNA
fragmentation was quantified by FACS analysis. SIP1 strongly
decreased UV-induced DNA fragmentation: the proportion of
cells in subG1 dropped from 46% to 20% (Fig. 3B). As expected,
DOX treatment of a parental rtTA-expressing clone had no effect
on cell survival. As cell interactions, including intercellular adhesion
mediated by cadherins, regulate cell viability (18), we speculated
that inhibition of cell-cell adhesion and EMT-associated changes in
cell morphology may have an impact on survival of UV-treated
cells. Ec1WVM, a dominant-negative E-cadherin mutant (19)
induced morphological transition in the squamous carcinoma cell
line A431 via functional inactivation of E- and P-cadherins (20).
Therefore, we expressed Ec1WVM in RT112 cells and analyzed its
effect on UV-induced apoptosis. Although Ec1WVM induced
cytoplasmic relocalization of E-cadherin and RT112/Ec1WVM
cells acquired mesenchymal cell shape (Fig. 3A), their sensitivity to
UV was not altered (Fig. 3B). To determine the extent of apoptosis
and confirm our DNA fragmentation results, we analyzed biochem-
ical hallmarks of apoptosis such as caspase activation and PARP
cleavage. Consistently with the DNA fragmentation data, we
observed that pro-caspase-3 and PARP cleavage was decreased in
UV-treated SIP1-expressing cells, but not in parental cells or in cells
expressing Ec1WVM (Fig. 3C).
SIP1 Protects Squamous Carcinoma Cells from DNA Damage-Induced
Apoptosis Independently of Cell Cycle Arrest. Arrest in the G1 phase
of the cell cycle can cause resistance to different apoptotic stimuli.
SIP1 induced accumulation of cells in G1 phase in RT112 cells (Fig.
S7) and, to a larger extent, in A431 squamous carcinoma cells (17).
Previously, we found that the underlying mechanism for this in
A431 cells was a direct repression of cyclin D1 transcription by SIP1.
Moreover, enforced expression of cyclin D1 uncoupled SIP1-
induced cell cycle arrest from EMT (17). To study the link between
the cell cycle control and anti-apoptotic functions of SIP1, and to
generalize the findings obtained in RT112 cells, we exploited
previously generated clones of A431 cells expressing SIP1; SIP1 and
cyclin D1 in combination or Ec1WVM. As a negative control, we
used A431 cells expressing SIP1ZFmut, a SIP1 mutant with an
inactivated C-terminal Zn finger domain. This mutant was incom-
petent in inducing EMT or cell cycle arrest (17). Consistent with the
data obtained in RT112 cells, expression of SIP1 strongly protected
A431 cells from DNA fragmentation (the proportion of cells in
subG1 has fallen from 47% to 12% in the presence of SIP1; Fig. 4A).
Interestingly, simultaneous induction of SIP1 and cyclin D1 inhib-
ited UV-induced DNA fragmentation to the same level, suggesting
that the anti-apoptotic activity of SIP1 is independent of cell cycle
progression. In agreement with the results generated in RT112
cells, induction of Ec1WVM in A431/Ec1WVM cells had no effect
Fig. 2. ZEB family members are differentially expressed in cultured cancer cells. (A) Transcription of genes coding for cadherins and ZEB family members was analyzed
in bladder cancer cell lines by semi quantitative RT-PCR. GAPDH was used as an internal control. (B) Western blot analysis of the expression of ZEB proteins and cadherins
in bladder cancer cell lines. A H1299 lung adenocarcinoma lysate was used as a positive control. To control for equal loading blots were probed with anti--tubulin
antibody. (C) Protein expression of SIP1, ZEB1, and E-cadherin in a panel of human cancer cell lines. Note the correlation of the presence of ZEB1 and absence of
E-cadherin. SIP1 expression was only detected in H1299, HOS, and SaOS-2 cell lines.
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on UV-induced DNA fragmentation (Fig. 4A), indicating that
anti-apototic function of SIP1 is independent of cell adhesion.
Similarly, A431 clones with constitutive Ec1WVM expression were
as sensitive to UV-induced apoptosis as epithelial A431 clones.
Predictably, expression of SIP1ZFmut had no effect on DNA
fragmentation (Fig. 4A). We observed that pro-caspase-3 and
PARP cleavage was decreased in UV-treated SIP1-expressing cells,
but not in cells expressing the SIP1ZFmut mutant or Ec1WVM. Of
note, the extent of cleavage was similar in A431/SIP1 and A431/
SIP1/cyclD1–2 cells, that is, apoptotic hallmarks were induced by
UV independently of the cell cycle (Fig. 4B).
SIP1 Interferes with Upstream Events in the Apoptotic Response.
After having demonstrated that SIP1 inhibits apoptotic hallmarks
in UV-treated cells, we aimed to examine upstream components of
the DNA damage response. Mitochondrial depolarization leading
to cytochrome c release is a central event in the apoptotic cascade
upstream of caspase-3 activation. We used TMRE staining and
Fig. 3. SIP1, but not a dominant negative E-cadherin mutant (Ec1WVM), protects RT112 cells from UV-induced apoptosis. (A) Ectopic expression of SIP1 and Ec1WVM
in RT112 cells. RT112/SIP1 cells were maintained with or without DOX for 48 h. Cells were immunostained with an anti-SIP1 antibody. RT112/Ec1WVM cells were stained
either with anti-myc antibody detecting mutant E-cadherin or with the anti-Ecadherin antibody recognising endogenous, but not mutant, E-cadherin (clone C20820;
BD Biosciences). Cells were counterstained with DAPI; and merged images are presented. (B) SIP1, but not Ec1WVM reduced the extent of DNA fragmentation in
UV-treated cells. RT112/SIP1, parental RT112/rtTA, and RT112/Ec1WVM were UV-treated (80 mJ/cm2) to induce apoptosis. RT112/SIP1 and RT112/rtTA cells were
maintained with or without DOX for 48 h before UV treatment. Cells were harvested, stained for DNA and analyzed by flow cytometry for subG1 DNA content; the
percentage of subG1 cells in each population is shown in the bar chart. The results show mean  SD of triplicate experiments. In some experiments DOX-treated
RT112/SIP1 cells were stained for SIP1, the fraction of SIP1-positive cells was gated and compared with the untreated and ungated cells. Flow cytometry profiles show
an example of decreased apoptosis in UV-treated cells gated for SIP1. (C and D) Analysis of PARP and pro-caspase 3 cleavage in RT112/SIP1, RT112/rtTA and
RT112/Ec1WVM cells. Cells were treated as described in B; and expression of caspase 3 and PARP was analyzed by western blotting (C) or immunofluorescence (D). Blots
were probed with an anti--Tubulin antibody to control for equal loading. Note decreased cleavage of caspase 3 and PARP in cells expressing SIP1.
Fig. 4. SIP1 has a G1 arrest-independent antiapoptotic activity in A431 cells. (A) Flow cytometry analyses of A431 cells with DOX-regulated expression of SIP1,
SIP1cyclin D1 (clone A431/SIP1/cyclD1–2), SIP1 mutant (SIP1ZFmut), or Ec1WVM. Cells with DOX-regulated expression of indicated proteins were maintained with or
without DOX for 48 h before UV treatment (60 mJ/cm2). 6 h after irradiation, the cells were harvested and analyzed by flow cytometry. The diagram shows the results
(mean  SD) of four independent experiments. (B) UV-induced PARP and caspase 3 cleavage in different A431 clones. DOX-treated and untreated cells were exposed
to UV and, at the indicated time points, cells were harvested and lysed. The expression of PARP, pro-caspase 3, SIP1, SIP1ZFmut, and Ec1WVM was analyzed by western
blotting. Anti--tubulin antibody was used to confirm equal loading.








flow cytometry to analyze mitochondrial membrane potential in
UV-treated RT112 and A431 cells with or without SIP1 expression.
In the absence of DOX, all cell lines analyzed demonstrated an
increase in the number of cells with depolarized mitochondria
reaching 70–80% in 4 h after UV treatment. Mitochondrial depo-
larization was strongly reduced by SIP1, but not by SIP1ZFmut or
Ec1WVM (Fig. S8). One of the most upstream events preceding
mitochondrial depolarization is the activation of ATM (ataxia-
telangiectasia mutated) and ATR (ATM- and Rad3-related) pro-
tein kinases, the sensors of DNA damage, which phosphorylate
target proteins and coordinate diverse cellular responses including
apoptosis. Rapid phosphorylation of a histone H2AX by ATM/
ATR kinases in response to both ionizing (21) and UV radiation
(22) is critical for the recognition of DNA lesions. Immunofluo-
rescent analyses of RT112 and A431 cells maintained for 2.5 h after
UV treatment have shown that -H2AX foci formation was com-
promised in SIP1-expressing cells (Fig. 5A). Western blotting
confirmed SIP1-mediated reduction in phosphorylation of H2AX
and another essential ATM/ATR target, p53, in A431 cells. Simi-
larly, phosphorylation of various other ATM/ATR substrates at a
common amino acid motif (serine/threonine followed by glutamine,
the [S/T]Q-motif) was delayed or inhibited by SIP1 (Fig. 5B). We
addressed whether expression of SIP1 has an effect on the extent
of DNA damage induced by UV. For these purposes we used the
alkali-denaturing comet assay, a method allowing to estimate levels
of single-strand DNA breaks in response to DNA-damaging agents.
SIP1-expressing and nonexpressing RT112 or A431 cells were
treated with different UV doses, immediately lysed and subjected
to the assay. The results show that UV-dependent DNA damage
was not affected by SIP1 (Fig. 5C).
Taken together, our data show that SIP1 suppresses all steps in
the DNA damage-induced apoptotic response, phosphorylation of
ATM/ATR substrates, mitochondrial depolarization, activation of
caspase-3, PARP cleavage and DNA fragmentation. However, it
does not affect the extent of DNA damage. The anti-apoptotic
activity of SIP1 is largely independent of its effects on cell adhesion
or cell cycle progression (Fig. 6).
Discussion
In agreement with the data previously obtained in breast cancer
cell lines (5, 23), transcription of both ZEB family members
correlated with mesenchymal characteristics of bladder carci-
noma cells. However, at the protein level, various mesenchymal
carcinoma cell lines of different origins expressed ZEB1 but not
SIP1. SIP1 has been shown to induce G1 phase cell cycle arrest
in squamous carcinoma cells by repressing cyclin D1 transcrip-
tion (17). Here we demonstrated that SIP1 significantly re-
pressed G1/S transition in RT112 cells, whereas the effect of
ZEB1 was insignificant. In hepatocellular carcinoma cells, SIP1
repressed hTERT, resulting in replicative senescence (24). In
contrast, ZEB1 was required for proliferation of mouse embryo
fibroblasts, and ZEB1/ mouse embryo fibroblasts underwent
premature replicative senescence (25). Differential expression of
ZEB1 and SIP1 proteins in carcinoma cell lines may reflect
selection for SIP1-negative cells during cell culture propagation.
ZEB1 plays an important role in carcinoma cells in vitro. Our
data show that ZEB1 is responsible for silencing E-cadherin
promoter in UMUC-3 cells in transient transfection assay (Fig. S4).
Enforced expression of either ZEB protein resulted in down-
regulation of epithelial cadherins, but ZEB1 depletion, although
retarding cell motility, was not sufficient for E-cadherin restoration
and mesenchymal-epithelial transition. These data suggest that
transient activation of ZEB proteins triggers EMT, but its mainte-
nance in growing tumors may require additional, possibly epige-
netic mechanisms. This is in agreement with the notion that DNA
methylation is involved in transcriptional silencing of E-cadherin
gene in bladder cancer cell lines and in tumor tissues (26).
Despite the absence of SIP1 in cultured carcinoma cells, negative
effects of SIP1 on cell cycle progression and its ability to induce
replicative senescence, the idea that SIP1 may function as a tumor
suppressor in bladder cancer is contradicted by the IHC data. We found
that SIP1 is highly expressed in bladder tumors and is an independent
predictor of poor cancer-specific survival. We observed a trend toward
a better local response in the bladder to radiotherapy in SIP1-negative
tumors. However, this trend could not be confirmed statistically,
possibly because of the relatively small sample size available for this
Fig. 5. SIP1 inhibits phosphorylation of ATM/ATR substrates without affecting
the degree of DNA damage. (A) RT112/SIP1 and A431/SIP1 cells were maintained
with or without DOX for 48 h, irradiated with 80 or 60 mJ/cm2 UV respectively,
incubated for 2.5 h, fixed and double-stained for SIP1 and -H2AX. (B) Western
blot analysis of phosphorylated ATM/ATR substrates in SIP1-expressing or non-
expressing A431 cells before and 2 h after UV treatment. (C) A431/SIP1 or RT112
cells were cultured with or without DOX for 48 h and treated with different UV
doses as indicated. A denaturing comet assay was performed and DNA was
stained and examined by fluorescence microscopy as described in SI Methods
section. The percentage of DNA in the tail of the comet (% tail DNA) was
calculated for each cell by the Komet Analysis software. Results are means  SD
of the four gels. Images show examples of UV-treated and -untreated nuclei.
Fig. 6. Scheme depicting effects of SIP1 and an E-cadherin dominant-negative
mutant on cell fate-regulating pathways. SIP1 and Ec1WVM activate cell motility,
morphological EMT, and expression of vimentin. SIP1, but not Ec1WVM, affects
cell fate by regulating cell proliferation, senescence, and DNA damage-induced
apoptosis.
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analysis. Because ZEB proteins activate tumor cell invasiveness (7, 10,
17) and survival (this study), we propose SIP1 as a biomarker of
biological aggressiveness and micrometastases. Further studies will
reveal whether SIP1 expression level is also a predictor of the response
to different treatment modalities.
Loss of E-cadherin expression is a central event in EMT pro-
grams. Its functional inhibition is sufficient to activate cell motility,
invasiveness and other aspects of EMT (20). Different mechanisms
such as somatic mutations or proteolytic cleavage by proteases
secreted by stromal cells can cause loss of E-cadherin in cancer and
trigger EMT-related programs (27, 28). The Ec1WVM mutant does
not affect cell viability, indicating that the susceptibility to apoptosis
can differ in cancer cells using different EMT pathways (Fig. 6).
Consistent with the previous study (16), we found that complete or
partial absence of E-cadherin staining correlated with tumor stage,
but not with patients’ survival. Overall, our data suggest that the
nature of an EMT pathway utilized by a given tumor defines the
aggressiveness of the disease.
We describe a biological activity of SIP1 in tumor cells, protection
from DNA damage-induced cell death. SIP1 suppresses mitochon-
drial depolarization, cleavage of PARP, pro-caspase 3, and phos-
phorylation of ATM/ATR substrates. In experiments with cells
ectopically expressing cyclin D1 and a dominant-negative form of
E-cadherin, Ec1WVM, we show that the anti-apoptotic activity of
SIP1 is largely independent of G1 arrest or functional inhibition of
epithelial junctional complex. Apoptosis resistance strongly con-
tributes to the clonal expansion of cancer cells in primary tumors
and is also important for malignant cells to disseminate and form
metastases (29). Among other proapoptotic stimuli present in
developing tumors, activated oncogenes may induce stalling and
collapse of DNA replication forks, DNA breakage and activation of
DNA damage response leading to apoptosis or senescence (30). We
hypothesize that SIP1 may contribute to tumor progression by
protecting cancer cells from apoptosis including DNA-damage-
dependent apoptotic pathways induced by activated oncogenes.
Therefore, the anti-apoptotic function of SIP1 may underlie the
frequent expression of SIP1 in bladder cancers and provide a
mechanistic explanation of the association between SIP1 immuno-
positivity and the disease aggressiveness. SIP1 is not a unique
EMT-inducing transcription factor in possessing anti-apoptotic
activity. In different systems, SNAIL and SLUG have been shown
to act as survival factors interfering with p53 and Akt pathways
(31–33). Moreover, down-regulation of PTEN is likely to be a part
of anti-apoptotic signaling activated by SNAIL (33). RT112 and
A431 cells used in this study contain mutant forms of p53; and SIP1
does not repress PTEN in these cells, suggesting that the above
mechanisms do not contribute to a cell survival pathway regulated
by SIP1. However, SIP1 inhibits H2AX foci formation and phos-
phorylation of ATM/ATR substrates, suggesting that it interferes
with upstream events in DNA damage pathways. Our data dem-
onstrating that a single protein (SIP1) can control both cell motility
and the response to DNA damage may shed light on the link
between cancer metastasis and genetic instability.
Materials and Methods
For subG1 DNA analysis, cells were trypsinized, pelleted, and fixed with 70%
ice-cold ethanol. After 2 h incubation at 20°C, cells were washed with PBS
and incubated for 30 min with primary antibody in FACS solution (0.5%
saponin, 3% BSA in PBS). Next, cells were washed three times with FACS
solution. Alexa-488 conjugated secondary antibodies were applied in FACS
solution for 30 min and cells were washed three times with FACS solution. To
stain for DNA, cells were incubated with 0.260 U RNase (in PBS) for 20 min
followed by 20 min incubation with 50 M propidium iodide (dissolved in PBS).
SubG1 DNA content was analyzed using a flow cytometer (FACSCalibur, BD
Biosciences).
For additional materials and methods see SI Methods.
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